文献速递银屑病与炎症性皮肤病

英夫利西单抗与英国和爱尔兰银屑病患者严重感染风险增加相关:来自英国皮肤科医师协会生物干预注册登记(BADBIR)的结果

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
PubMed 文献 · Br J Dermatol · 2018-10-21

研究比较英夫利西单抗与非生物系统治疗在慢性斑块状银屑病患者中严重感染的风险。英夫利西单抗组严重感染发生率为每1000人年47.8例(95%CI 35.7-64.0),非生物系统治疗组为每1000人年14.2例(95%CI 11.5-17.4)。校正后英夫利西单抗组严重感染风险增加(adjHR 1.95,95%CI 1.01-3.75)。

要点

  • 英夫利西单抗组严重感染发生率为每1000人年47.8例,高于非生物系统治疗组的每1000人年14.2例
  • 英夫利西单抗组严重感染校正后风险增加(adjHR 1.95,95%CI 1.01-3.75)
  • 治疗前6个月严重感染风险更高(adjHR 3.49,95%CI 1.14-10.70)

核心结论

  • 在英国和爱尔兰的银屑病患者中,英夫利西单抗与非生物系统治疗相比与严重感染风险增加相关。

研究设计与样本

  • 前瞻性队列研究,使用英国皮肤科医师协会生物干预注册登记(BADBIR)的数据。
  • 英夫利西单抗与非生物系统治疗(包括甲氨蝶呤、环孢素、阿维A、富马酸酯、补骨脂素-紫外线A或羟基脲的任何暴露)进行比较。
  • 共纳入3843名参与者进行分析,截止至2016年10月。
  • 采用倾向评分逆概率治疗加权校正预先确定的协变量,计算Cox比例风险模型的风险比(HR)。

主要发现

  • 英夫利西单抗组严重感染发生率为每1000人年47.8例(95%CI 35.7-64.0),非生物系统治疗组为每1000人年14.2例(95%CI 11.5-17.4)。
  • 英夫利西单抗相比非生物系统治疗总体严重感染风险增加(adjHR 1.95,95%CI 1.01-3.75)。
  • 英夫利西单抗相比仅甲氨蝶呤治疗严重感染风险增加(adjHR 2.96,95%CI 1.58-5.57)。
  • 英夫利西单抗治疗前6个月严重感染风险更高(adjHR 3.49,95%CI 1.14-10.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on nonbiologic systemic therapies. METHODS: A prospective cohort study was performed using data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Infliximab was compared with nonbiologic systemic therapies, inclusive of any exposure to methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A or hydroxycarbamide. Serious infections were those associated with hospitalization, the use of intravenous antimicrobial therapy and/or those that led to death. Propensity score inverse probability treatment weights were used to adjust for potential confounding from a priori identified covariates. Cox proportional hazards models were calculated to obtain hazard ratios (HRs). RESULTS: In total, 3843 participants were included for analysis up to October 2016. The incidence rates were significantly higher in the infliximab cohort (47·8 per 1000 person-years) [95% confidence interval (CI) 35·7-64·0], compared with 14·2 per 1000 person-years (95% CI 11·5-17·4) in the nonbiologic systemic cohort. Infliximab was associated with an overall increase in the risk of serious infection compared with nonbiologics [adjusted HR (adjHR) 1·95, 95% CI 1·01-3·75] and methotrexate only (adjHR 2·96, 95% CI 1·58-5·57) and a higher risk of serious infection in the first 6 months of therapy (adjHR 3·49, 95% CI 1·14-10·70). CONCLUSIONS: Infliximab is associated with an increased risk of serious infections compared with nonbiologic systemic therapies in patients with psoriasis in the U.K. and the Republic of Ireland.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Yiu ZZN, Ashcroft DM, Evans I, et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2018. PMID: 30070708. doi:10.1111/bjd.17036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。